Key points are not available for this paper at this time.
Targeting Fyn can reverse memory deficits found in AD mouse models, and rescue synapse density loss characteristic of the disease. Thus, AZD0530 is a promising candidate to test as a potential therapy for AD.
Kaufman et al. (Tue,) studied this question.